Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 461

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

Open access
Kosiborod, Mikhail, Lam, Carolyn S.P., Kohsaka, Shun, Kim, Dae Jung, Karasik, Avraham, Shaw, Jonathan, Tangri, Navdeep, Goh, Su-Yen, Thuresson, Marcus, Chen, Hungta, Surmont, Filip, Hammar, Niklas, Fenici, Peter, Kosiborod, Mikhail, Cavender, Matthew A., Fu, Alex Z., Wilding, John P., Khunti, Kamlesh, Norhammar, Anna, Birkeland, Kåre, Jørgensen, Marit Eika, Holl, Reinhard W., Lam, Carolyn SP, Gulseth, Hanne Løvdal, Carstensen, Bendix, Bollow, Esther, Franch-Nadal, Josep, García Rodríguez, Luis Alberto, Karasik, Avraham, Tangri, Navdeep, Kohsaka, Shun, Kim, Dae Jung, Shaw, Jonathan, Arnold, Suzanne, Goh, Su-Yen, Hammar, Niklas, Fenici, Peter, Bodegård, Johan, Chen, Hungta, Surmont, Filip, Nahrebne, Kyle, Blak, Betina T., Wittbrodt, Eric T., Saathoff, Matthias, Noguchi, Yusuke, Tan, Donna, Williams, Maro, Lee, Hye Won, Greenbloom, Maya, Kaidanovich-Beilin, Oksana, Yeo, Khung Keong, Bee, Yong Mong, Khoo, Joan, Koong, Agnes, Lau, Yee How, Gao, Fei, Tan, Wee Boon, Kadir, Hanis Abdul, Ha, Kyoung Hwa, Lee, Jinhee, Chodick, Gabriel, Melzer Cohen, Cheli, Whitlock, Reid, Cea Soriano, Lucia, Fernándex Cantero, Oscar, Riehle, Ellen, Ilomaki, Jennie, Magliano, Dianna·2018·Journal of the American College of Cardiology

Abstract

BACKGROUND: Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data suggested similar SGLT-2i effects in T2D patients with a broader risk profile, but these studies focused on heart failure and death and were limited to the United States and Europe. OBJECTIVES: The purpose of this study was to examine a broad range of CV outcomes in patients initiated on SGLT-2i versus other glucose-lowering drugs (oGLDs) across 6 countries in the Asia Pacific, the Middle East, and North American regions. METHODS: New users of SGLT-2i and oGLDs were identified via claims, medical records, and national registries in South Korea, Japan, Singapore, Israel, Australia, and Canada. Propensity scores for SGLT-2i initiation were developed in each country, with 1:1 matching. Hazard ratios (HRs) for death, hospitalization for heart failure (HHF), death or HHF, MI, and stroke were assessed by country and pooled using weighted meta-analysis. RESULTS: After propensity-matching, there were 235,064 episodes of treatment initiation in each group; ∼27% had established CV disease. Patient characteristics were well-balanced between groups. Dapagliflozin, empagliflozin, ipragliflozin, canagliflozin, tofogliflozin, and luseogliflozin accounted for 75%, 9%, 8%, 4%, 3%, and 1% of exposure time in the SGLT-2i group, respectively. Use of SGLT-2i versus oGLDs was associated with a lower risk of death (HR: 0.51; 95% confidence interval [CI]: 0.37 to 0.70; p < 0.001), HHF (HR: 0.64; 95% CI: 0.50 to 0.82; p = 0.001), death or HHF (HR: 0.60; 95% CI: 0.47 to 0.76; p < 0.001), MI (HR: 0.81; 95% CI: 0.74 to 0.88; p < 0.001), and stroke (HR: 0.68; 95% CI: 0.55 to 0.84; p < 0.001). Results were directionally consistent across both countries and patient subgroups, including those with and without CV disease. CONCLUSIONS: In this large, international study of patients with T2D from the Asia Pacific, the Middle East, and North America, initiation of SGLT-2i was associated with a lower risk of CV events across a broad range of outcomes and patient characteristics. (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors [CVD-REAL]; NCT02993614).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2018.03.009

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 461

Metadata

Authors
Kosiborod, M., Lam, C. S. P., Kohsaka, S., Kim, D. J., Karasik, A., Shaw, J., Tangri, N., Goh, S.-Y., Thuresson, M., Chen, H., Surmont, F., Hammar, N., Fenici, P., Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Norhammar, A., Birkeland, K., Jørgensen, M. E., Holl, R. W., Lam, C. S., Gulseth, H. L., Carstensen, B., Bollow, E., Franch-Nadal, J., García Rodríguez, L. A., Karasik, A., Tangri, N., Kohsaka, S., Kim, D. J., Shaw, J., Arnold, S., Goh, S.-Y., Hammar, N., Fenici, P., Bodegård, J., Chen, H., Surmont, F., Nahrebne, K., Blak, B. T., Wittbrodt, E. T., Saathoff, M., Noguchi, Y., Tan, D., Williams, M., Lee, H. W., Greenbloom, M., Kaidanovich-Beilin, O., Yeo, K. K., Bee, Y. M., Khoo, J., Koong, A., Lau, Y. H., Gao, F., Tan, W. B., Kadir, H. A., Ha, K. H., Lee, J., Chodick, G., Melzer Cohen, C., Whitlock, R., Cea Soriano, L., Fernándex Cantero, O., Riehle, E., Ilomaki, J., & Magliano, D.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2018-06
Volume
71
Issue
23
Pages
2628-2639
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2808467887
Cited by
461
References
27
FWCI
49.80
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. https://app.cochat.ai/papers/10.1016/j.jacc.2018.03.009
The paper
Kosiborod, M., Lam, C. S. P., Kohsaka, S., Kim, D. J., Karasik, A., Shaw, J., Tangri, N., Goh, S.-Y., Thuresson, M., Chen, H., Surmont, F., Hammar, N., Fenici, P., Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Norhammar, A., . . . Magliano, D. (2018). Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2018.03.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.